Asthma Therapeutics in Major Developed Market Size & Share to 2020 - PowerPoint PPT Presentation

View by Category
About This Presentation
Title:

Asthma Therapeutics in Major Developed Market Size & Share to 2020

Description:

GBI Research, a leading business intelligence provider, has released its latest research report, Asthma Therapeutics in Major Developed Markets to 2020 - Personalized Treatment for Severe Asthma to Drive Market Growth despite Patent Expirations. The asthma therapeutics market is forecast to grow marginally over the forecast period across the top eight developed nations, from $18.4 billion in 2013 to a projected value of $21.7 billion by 2020 at a Compound Annual Growth Rate (CAGR) of 2.4%. Enquiry @ – PowerPoint PPT presentation

Number of Views:37

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Asthma Therapeutics in Major Developed Market Size & Share to 2020


1
Asthma Therapeutics in Major Developed Markets to
2020 - Personalized Treatment for Severe Asthma
to Drive Market Growth despite Patent Expirations
No. Pages 142
Published on February - 2015
2
.
Report Overview
About Asthma Therapeutics in Major Developed
Markets to 2020 Research Beam added a report
Asthma Therapeutics in Major Developed Markets
to 2020 - Personalized Treatment for Severe
Asthma to Drive Market Growth despite Patent
Expirations. Summary GBI Research, a leading
business intelligence provider, has released its
latest research report, Asthma Therapeutics in
Major Developed Markets to 2020 - Personalized
Treatment for Severe Asthma to Drive Market
Growth despite Patent Expirations. The asthma
therapeutics market is forecast to grow
marginally over the forecast period across the
top eight developed nations, from 18.4 billion
in 2013 to a projected value of 21.7 billion by
2020 at a Compound Annual Growth Rate (CAGR) of
2.4. This is in spite of generic erosion facing
several of the leading asthma brands, such as
Advair (fluticasone propionate/salmeterol
xinafoate), Symbicort (budesonide/formoterol
fumarate) and Xolair (omalizumab), and is a
consequence of new market entrants and rising
disease prevalence. Get Full Details On
http//www.researchbeam.com/asthma-therapeutics-in
-major-developed-to-2020-personalized-treatment-fo
r-severe-asthma-to-drive-growth-despite-patent-exp
irations-market
3
.
Report Overview
The global prevalence of asthma is significant,
believed to affect approximately 300 million
people worldwide. This burden is predicted to
increase in future, reaching 400 million by
2025.   Although the majority of asthma patients
are able to manage their symptoms effectively
using currently marketed products, some remain
inadequately controlled with these same products.
This unmet need, coupled with rising global
prevalence, has resulted in strong industry
interest.   Consequently, the current asthma
pipeline is highly innovative, featuring several
promising molecules in late-stage drug
development. Biologics and monoclonal antibodies,
the latter in particular, are gaining prominence
within the indication. Novel monoclonal
antibodies such as mepolizumab, reslizumab,
lebrikizumab, and dupilumab target Interleukins
(IL), or IL receptors, and have demonstrated
potential in severe and inadequately controlled
eosinophilic asthma, in turn representing a shift
towards personalized therapy. Despite the fact
that they target only a small patient sub-set,
they are likely to be priced highly and to drive
market growth, offsetting the impact of generic
erosion.
4
.
Report Overview
  • Scope
  • The report covers and includes -
  • - An introduction to asthma, including discussion
    of disease epidemiology, etiology
    pathophysiology, symptoms, diagnosis, and
    treatment, with clinical data for drugs featured
    in the current treatment algorithm discussed in
    detail
  • - In-depth analysis of the current marketed
    products landscape, including product profiles of
    the main drugs used and heat maps that compare
    their safety and efficacy parameters
  • - Comprehensive analysis of the asthma pipeline
    by phase of development, molecule type, and
    molecular target and novelty, and comparative
    analysis of the most promising late-stage
    pipeline drugs, as well as heat maps and a
    competitor matrix that compares safety and
    efficacy parameters
  • - Additional in-depth analysis of the asthma
    clinical trials landscape, including trends in
    size, duration and failure rate
  • - Forecast projections for the asthma market to
    2020, including analysis of the global market and
    each of the eight major markets and incorporating
    projected, low, and high-variance scenarios based
    on
  •  

5
Report Overview
  • treatment usage patterns and annual cost of
    therapy in each of the major markets
  • Discussion of the strategic consolidations
    landscape, including trends in co-development and
    licensing deals relevant to asthma drug products
  • Reasons to buy
  •  
  • The report will assist business development and
    enable marketing executives to strategize their
    product launches by allowing them to -
  • - Gain a comprehensive understanding of asthma,
    including diagnosis, disease severity, and
    treatment algorithms
  • - Understand the current asthma marketed products
    landscape and recognize the dominant therapeutic
    agents and pharmaceutical players involved
  • - Identify trends, developments, and prominent
    molecule types and molecular targets within the
    asthma pipeline
  •  

6
Report Overview
  • - Gain an appreciation of the clinical and
    commercial aspects of the most promising
    late-stage pipeline molecules and their potential
    competitive impact on the future market
  • - Consider market opportunities and potential
    risks by examining trends in asthma clinical
    trial size, duration and failure rate, phase of
    development, molecule type, and molecular target
  • - Observe projections for treatment usage
    patterns, annual therapy costs, and market growth
    in the eight major markets and understand reasons
    for variance in projected patterns of growth
  •  

7
Table Of Contents
1 Table of Contents 5 1.1 List of Tables 7 1.2
List of Figures 8 2 Introduction 10 2.1 Disease
Introduction 10 2.2 Epidemiology 10 2.3 Etiology
11 2.4 Pathophysiology 12 2.5 Symptoms 12 2.6
Diagnosis 12 2.7 Assessment of Disease Severity
13 2.8 Treatment 15 2.9 Treatment Algorithm 16
8
Table Of Contents
2.10 Treatment Segments 18 2.10.1 ICS Monotherapy
for the Maintenance Treatment of Asthma 19 2.10.2
Singulair (montelukast sodium) as First-Line
Maintenance Therapy 21 2.10.3 ICS/LABA
Combination Therapy 22 2.10.4 Add-on Therapies
27 3 Marketed Products 33 3.1 Overview 33 3.2 ICS
for the Maintenance Treatment of Asthma 33 3.2.1
Arnuity (fluticasone furoate) - GSK 33 3.3
ICS/LABA Combination Therapy for the Maintenance
Treatment of Asthma 34 3.3.1 Advair (fluticasone
propionate and salmeterol xinafoate) - GSK
34 Enquiry about this report _at_ http//www.research
beam.com/asthma-therapeutics-in-major-developed-to
-2020-personalized-treatment-for-severe-asthma-to-
drive-growth-despite-patent-expirations-market/enq
uire-about-report
9
FOR MORE DETAILS
Visit us at
http//www.researchbeam.com/asthma-therapeutics-in
-major-developed-to-2020-personalized-treatment-fo
r-severe-asthma-to-drive-growth-despite-patent-exp
irations-market
Stay With Us
5933 NE Win Sivers Drive, 205, Portland, OR
97220 United States
TELEPHONE 1 (800) 910-6452 E-MAIL
sales_at_researchbeam.com
About PowerShow.com